Hyperlipidemias: Clinical Trials

13 trials for Hyperlipidemias, newest first

ClinicalTrials Daily  ·  Areas  ·  Conditions  ·  Drugs  ·  Sponsors  ·  

13 terminated. 13 Phase 4.

By phase and status

PhaseTrialsStatus
Phase 413Terminated 13

Follow Hyperlipidemias: new trials by email Literature Review of Hyperlipidemias trials Research Report on Hyperlipidemias

Trials (filtered) newest first · largest first

All 13 trials

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

TrialPhaseStatusSponsorEnrollmentStartUpdated
The CHORAL Flow Study
Evolocumab, Placebo - Coronary Artery Disease, Atherosclerosis
Phase 4TerminatedImperial College London122019-09-112024-08-06
Impact of LDL-cholesterol Lowering on Platelet Activation
Evolocumab - Familial Hypercholesterolemia
Phase 4TerminatedColumbia University42018-11-162021-04-01
Investigating the Effects of Lipid-therapy Intensification With Alirocumab on Endothelial Function, Carotid Arteries, Lipoprotein Particle Subfractions, Inflammation and Post-prandial Lipemia
Magnet Resonance Tomography, Carotid Arteries Sonography, Flow-mediated Dilation, Fat-tolerance Test, Laboratory Testing - Atherosclerosis, Hypercholesterolemia
Phase 4TerminatedMedical University of Graz242018-06-202020-04-24
Anti-inflammatory Effects of Simvastatin
Simvastatin 40mg, Ezetimibe 10mg - Inflammation, Atherosclerosis
Phase 4Terminatedparesh Dandona102017-05-012024-11-08
Study Evaluating Novel Biomarkers of AKI (Acute Kidney Injury) in Post-operative Patients
Nephro Check Test, serum creatinine measurement - Acute Kidney Injury, Arterial Hypertension
Phase 4TerminatedUniversitair Ziekenhuis Brussel1002015-04-012018-10-15
Effect of Niacin/Laropiprant on Postprandial Lipoprotein Metabolism in Patients With Dyslipoproteinemia
Niacin/ Laropiprant - Hyperlipoproteinemia, Metabolic Syndrome
Phase 4TerminatedLudwig-Maximilians - University of Munich122011-06-012014-04-10
Evaluating the Efficacy and Safety of Dehypotin® in the Patients With Type 2 Diabetes Mellitus or Cardiovascular Disease
Placebo, Dehypotin - Type 2 Diabetes Mellitus, Cardiovascular Disease
Phase 4TerminatedNang Kuang Pharmaceutical Co., Ltd.602010-05-012011-06-09
The Effect of Atorvastatin on Endothelial Cell Dysfunction in Chronic Kidney Disease
Atorvastatin - Chronic Kidney Disease, High Cholesterol
Phase 4TerminatedDuke University12008-02-012014-07-03
Study of Asian Patients With Hypercholesterolaemia in the UK - Rosuvastatin 5mg Versus Atorvastatin 10mg
Dietary advice, rosuvastatin, atorvastatin - Hypercholesterolaemia
Phase 4TerminatedAstraZeneca552006-12-012010-12-16
Randomized Trial Comparing N of 1 Trials to Standard Practice to Improve Adherence to Statins in Patients With Diabetes
N of 1 Trials - Diabetes, Cardiovascular Disease
Phase 4TerminatedLondon Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph's62006-09-012008-01-08
Switching to Rosuvastatin Versus Adding Ezetimibe to Atorvastatin Versus Doubling the Dose of Atorvastatin in Patients With Hypercholesterolemia and Risk Factors (P03708)
Rosuvastatin, Ezetimibe + Atorvastatin, Double Atorvastatin - Hypercholesterolemia, Atherosclerosis
Phase 4TerminatedOrganon and Co872004-09-012024-08-15
Ezetimibe Plus Simvastatin Versus Simvastatin in Patients With Hypercholesterolemia and Coronary Risk Factors (P03405)
Ezetimibe, Placebo - Hypercholesterolemia, Atherosclerosis
Phase 4TerminatedOrganon and Co822004-01-012022-02-17
Atorvastatin and LDL Profile in Non-Insulin Dependent Diabetes Mellitus
Atorvastatin, Placebo - Hyperlipidemia, Diabetes Mellitus, Type 2
Phase 4TerminatedPfizer's Upjohn has merged with Mylan to form Viatris Inc.412003-03-012021-02-18

Narrower conditions

Hypercholesterolemia (9)  ·  Atherosclerosis (5)  ·  Cardiovascular Diseases (3)  ·  Coronary Artery Disease (2)  ·  Diabetes Mellitus (2)  ·  Diabetes Mellitus, Type 2 (2)  ·  Acute Kidney Injury (1)  ·  Hyperlipoproteinemia Type II (1)  ·  Hyperlipoproteinemias (1)  ·  Hypertension (1)  ·  Inflammation (1)  ·  Metabolic Syndrome (1)  ·  Obesity (1)  ·  Renal Insufficiency, Chronic (1)

Broader conditions

Dyslipidemias (13)  ·  Lipid Metabolism Disorders (13)  ·  Metabolic Diseases (13)  ·  Nutritional and Metabolic Diseases (13)  ·  Vascular Diseases (7)  ·  Cardiovascular Diseases (6)  ·  Arterial Occlusive Diseases (5)  ·  Arteriosclerosis (5)  ·  Glucose Metabolism Disorders (5)  ·  Endocrine System Diseases (4)  ·  Pathological Conditions, Signs and Symptoms (3)  ·  Coronary Disease (2)  ·  Diabetes Mellitus (2)  ·  Female Urogenital Diseases (2)

Interventions

Atorvastatin (4)  ·  Ezetimibe (3)  ·  Rosuvastatin Calcium (2)  ·  evolocumab (2)  ·  MK-0524 (1)  ·  Niacin (1)  ·  Nutrition Assessment (1)  ·  Simvastatin (1)  ·  Single-Case Studies as Topic (1)

Sponsors

Organon and Co (2)  ·  AstraZeneca (1)  ·  Columbia University (1)  ·  Duke University (1)  ·  Imperial College London (1)  ·  London Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph's (1)  ·  Ludwig-Maximilians - University of Munich (1)  ·  Medical University of Graz (1)  ·  Nang Kuang Pharmaceutical Co., Ltd. (1)  ·  Pfizer's Upjohn has merged with Mylan to form Viatris Inc. (1)  ·  Universitair Ziekenhuis Brussel (1)  ·  paresh Dandona (1)

Countries

Germany (2)  ·  United Kingdom (2)  ·  United States (2)  ·  Austria (1)  ·  Belgium (1)  ·  Canada (1)  ·  Taiwan (1)

Top investigators

Charlotte G McDonald, MD (1)  ·  Henry Ginsberg, MD (1)  ·  Henry Seligman, MBBS (1)  ·  Jan Poelaert, Prof.Dr. (1)  ·  Klaus Parhofer, MD, Prof. (1)  ·  Lien Torisaen, MD (1)  ·  Lynda Szczech, MD (1)  ·  Nan Wang, PhD (1)  ·  Paresh Dandona, MD, PhD (1)  ·  Rhiannon Rowsell, MD (1)  ·  Ricardo Petraco, PhD (1)  ·  Shahid Ali, MD (1)  ·  Yang Wei Shiung (1)

NIH funding

2018 (1)